Medtronic Plc. · NYSE:MDT
Medtronic — Q3 FY16 Earnings Presentation
8 slides from Medtronic's earnings presentation, Mar 1, 2016
Slide 1: Medtronic plc Q3 FY16 Consolidated Results and Group Revenue Highlights
MEDTRONIC PLC Q3 FY16 CONSOLIDATED RESULTS AND GROUP REVENUE HIGHLIGHTS Exhibit 99.2
Slide 2: Forward Looking Statements
Q3 FY16 Earnings Results | March 1, 2016 | 2 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements which provide current expectations or forecasts, including those relating to market and sales growth, growth strategies, financial results, use of free cash flow, product dev
Slide 3: MDT Q3 FY16 Highlights: Solid Performance in Q3
Q3 FY16 Earnings Results | March 1, 2016 | 3 Sustained execution results in another quarter of market outperformance • Revenue growth of 6% in the upper half of our mid-single digit expectation • Acquisitions & divestitures contributed a net 20 bps to Q3 revenue growth • Foreign currency translati
Slide 4: Cardiac and Vascular Group (CVG)
Q3 FY16 Earnings Results | March 1, 2016 | 4 CVG Q3 FY16 HIGHLIGHTS CRHF 53% CSH 31% APV 16% U.S. 52% Non- U.S. Dev 32% EM 16% Cardiac Rhythm & Heart Failure (CRHF) KEY PERFORMANCE DRIVERS1 High Power – LSD Decline • Highest US share since Q4FY10 • ICDs: HSD growth – US Evera MRI™, • CRT-D: HSD de
Slide 5: MITG Surgical Solutions
Q3 FY16 Earnings Results | March 1, 2016 | 5 MITG Q3 FY16 HIGHLIGHTS Surgical Solutions KEY PERFORMANCE DRIVERS1 Strong, At or Above Market Growth Performance Patient Monitoring & Recovery (PMR) Advanced Surgical – HSD • Continues to benefit from new products and the continued shift from open to mi
Slide 6: RTG: Strong NV & ST Growth Offsetting Declines in Neuromodulation and Spine
Q3 FY16 Earnings Results | March 1, 2016 | 6 RTG Q3 FY16 HIGHLIGHTS Spine 40% Neuro 27% ST 25% NV 8% US 69% Non-US Dev 21% EM 10% KEY PERFORMANCE DRIVERS1 Strong NV & ST Growth Offsetting Declines in Neuromodulation and Spine Drug Pump – LDD Decline • Continued challenges based on the FDA consent d
Slide 7: Diabetes Group
Q3 FY16 Earnings Results | March 1, 2016 | 7 DIABETES Q3 FY16 HIGHLIGHTS US 62% Non-US Dev 30% EM 8% KEY PERFORMANCE DRIVERS1 Intensive Insulin Management (IIM) Strong, Broad-Based Performance Across All Three Divisions MiniMed® 530G MiniMed® Connect 7 Total Group Revenue $474M Revenue $M As Rep Y/Y
Slide 8: Appendix: Acronyms / Abbreviations and Key Performance Drivers
Q3 FY16 Earnings Results | March 1, 2016 | 8 APPENDIX ACRONYMS / ABBREVIATIONS KEY PERFORMANCE DRIVERS 1 Growth DD Double Digits HSD High-Single Digit LDD Low-Double Digits LSD Low-Single Digit MSD Mid-Single Digit Other Bps Basis Points CC Constant Currency CY Calendar Year Dev Developed EM Emergin